KORU Medical Systems, Inc. (KRMD)

The investment thesis here hinges entirely on the company's operational turnaround rather than financial stability. Fundamentally, the business is showing signs of life with revenue surging nearly 100% year-over-year and gross margins expanding to healthy levels above 60%. However, the balance sheet remains fragile with negative operating income and a forward P/E that implies massive future earnings growth to justify the current price. The market seems to be pricing in a complete recovery, yet the path from a loss-making entity to a profitable one is steep. Short-term, the stock is technically weak, trading well below its 50-day and 200-day averages, which creates a heavy overhead resistance zone. Despite this, the options market is screaming bullishness, with heavy call buying at the $5.0 level acting as a self-fulfilling prophecy for a rebound. This divergence suggests smart money is accumulating on weakness, betting that the recent revenue acceleration will eventually translate into profitability. Long-term, I am cautiously optimistic but not convinced enough for a full 'buy' rating. While the revenue trajectory is exceptional and the product niche appears viable, the lack of a dividend and the persistent losses mean this is a pure growth gamble. It is a speculative play on a turnaround story that has finally gained traction, but the risk of execution failure or margin compression remains high until consistent profitability is demonstrated.